1999
DOI: 10.1385/ijgc:25:1:45
|View full text |Cite
|
Sign up to set email alerts
|

Treatment with Lexipafant Ameliorates the Severity of Pancreatic Microvascular Endothelial Barrier Dysfunction in Rats with Acute Hemorrhagic Pancreatitis

Abstract: Pretreatment with lexipafant, a potent PAF receptor antagonist, significantly reduced the pancreatitis-induced increase in pancreatic endothelial barrier dysfunction, pancreatic leukocyte recruitment and serum levels of IL-1 beta, although a difference persisted between animals with sham operation and pancreatitis.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
12
0

Year Published

2000
2000
2007
2007

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 24 publications
(12 citation statements)
references
References 12 publications
0
12
0
Order By: Relevance
“…Several animal models of pancreatitis have shown that hemoconcentration is associated with the microcirculatory compromise that contributes to the tissue damage seen in acute pancreatitis (35)(36)(37). A number of therapeutic interventions aimed at correcting hemoconcentration have been studied in this critical period (9,35,(38)(39)(40)(41)(42). Our study, however, did not show any difference in those patients whose hemoconcentration was corrected versus those in whom it was not, and volume of fluid given in the first 24 hr was not associated with prognosis.…”
Section: Discussionmentioning
confidence: 99%
“…Several animal models of pancreatitis have shown that hemoconcentration is associated with the microcirculatory compromise that contributes to the tissue damage seen in acute pancreatitis (35)(36)(37). A number of therapeutic interventions aimed at correcting hemoconcentration have been studied in this critical period (9,35,(38)(39)(40)(41)(42). Our study, however, did not show any difference in those patients whose hemoconcentration was corrected versus those in whom it was not, and volume of fluid given in the first 24 hr was not associated with prognosis.…”
Section: Discussionmentioning
confidence: 99%
“…Furthermore, PAF seems to be partly involved in the activation of the protease-antiprotease system [21]. Numerous studies support the belief that PAF antagonists help preserve mucosal barrier function in both physiological and pathophysiological conditions, possibly by triggering endothelial and epithelial barrier permeability [8,9,21,22], or inhibiting tissue leukocyte recruitment in the small intestine and colon [22,23]. In the present study, we investigated the effect of PAF receptor antagonists on BT in acute edematous pancreatitis.…”
Section: Discussionmentioning
confidence: 93%
“…PAF seems to be involved in the release of cytokines, such as IL-1 and IL-6. Wang et al [8] have shown that intestinal epithelial damage occurs in AP and PAF antagonists decrease this damage as well as serum IL-1 levels. Liu et al [32] have shown that the PAF antagonist, BB-882, decreases BT but not TNF-· in acute necrotizing pancreatitis.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…), arachidonic acids metabolites, as well as other activated fluid and cellular substances (free oxygen radicals, lysozyme, cytokines, etc.). Current studies have shown that PAF may transmit signals and exert its biological effects through the signal transduction system consisting of PAF-R, G-protein, and membrane effector enzyme [14] . PAF-R was found in the ligand-binding experiment of [15] .…”
Section: Xia Sh Et Al Effect Of Bn52021 On Paf-r In Pancreatitismentioning
confidence: 99%